Company highlights
- Mature pipeline with two phase III drugs and one in
registration
- Seven products in clinical development
- Potential for earlier approval of first product, in 2009
- ASA404: partnered with Novartis
– with
blockbuster potential in lung cancer
– US
co-marketing option with Novartis
– target
2011 filing
- Xanafide: potential first product registration for secondary
AML
- Oral fludarabine: attractive low-risk niche oncology
opportunity
- AS1411: first aptamer in oncology, with broad potential
- Flt3 program: attractive divestible asset in auto-immune
diseases
- Strong cash position to support all priority programs
Back to top